Ventures L. P. BioAdvance is 10% at NUPATHE INC. (PATH). They have made 1 open-market trade across 1 company since 2012, most recently 2012-10-17.
CIK 0001302567
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PATH | 306,472 | $3.9M |
Shares reported on the most recent Form 4, priced at the 2012-10-17 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PATH | SELL | 2012-10-15 | 2012-10-17 | $3.35 | $746K | +9.9% | +5.3% | +5.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.